Sushil Patel
CIK: 0001860609
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (22 total)
- Aug 10, 2026REPL
Replimune Group, Inc.
Sale(S)Direct39.3K shares at avg. $12.97$510K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct881 shares at avg. $192.61$170K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct541 shares at avg. $191.87$104K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct600 shares at avg. $190.54$114K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct100 shares at avg. $188.57$19K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct1.1K shares at avg. $185.90$204K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct858 shares at avg. $186.92$160K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct300 shares at avg. $187.83$56K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Exercise(M)Direct3K shares at avg. $37.54$111K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct300 shares at avg. $183.17$55K - Jun 29, 2026RVMD
Revolution Medicines, Inc.
Sale(S)Direct900 shares at avg. $184.59$166K - Jun 18, 2026RVMD
Revolution Medicines, Inc.
Award(A)Direct1.2K shares- - May 18, 2026REPL
Replimune Group, Inc.
Sale(S)Direct37.3K shares at avg. $5.08$190K - Apr 1, 2026REPL
Replimune Group, Inc.
Award(A)Direct251.2K shares- - Dec 19, 2025REPL
Replimune Group, Inc.
Award(A)Direct200K shares- - Dec 2, 2025REPL
Replimune Group, Inc.
Sale(S)Direct10K shares at avg. $11.13$111K - Jun 26, 2025RVMD
Revolution Medicines, Inc.
Award(A)Direct3.1K shares- - May 20, 2025REPL
Replimune Group, Inc.
Sale(S)Direct25.1K shares at avg. $8.06$202K - Apr 1, 2025REPL
Replimune Group, Inc.
Award(A)Direct166.7K shares- - Dec 16, 2024REPL
Replimune Group, Inc.
Sale(S)Direct10K shares at avg. $12.42$124K - Oct 31, 2024RVMD
Revolution Medicines, Inc.
Exercise(M)Direct5K shares at avg. $24.84$124K - Oct 31, 2024RVMD
Revolution Medicines, Inc.
Sale(S)Direct5K shares at avg. $54.14$271K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  REPL Replimune Group, Inc. | Sale(S) | 39,341 | $12.97 | $510,253 | Direct |
| Jun 29, 2026 |  RVMD Revolution Medicines, Inc. | Sale(S) | 881 | $192.61 | $169,693 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 541 | $191.87 | $103,800 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 600 | $190.54 | $114,327 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 100 | $188.57 | $18,857 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 1,100 | $185.90 | $204,489 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 858 | $186.92 | $160,374 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 300 | $187.83 | $56,348 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Exercise(M) | 2,955 | $37.54 | $110,931 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 300 | $183.17 | $54,952 | Direct |
| Jun 29, 2026 | RVMD Revolution Medicines, Inc. | Sale(S) | 900 | $184.59 | $166,128 | Direct |
| Jun 18, 2026 | RVMD Revolution Medicines, Inc. | Award(A) | 1,191 | - | $0 | Direct |
| May 18, 2026 | REPL Replimune Group, Inc. | Sale(S) | 37,324 | $5.08 | $189,606 | Direct |
| Apr 1, 2026 | REPL Replimune Group, Inc. | Award(A) | 251,240 | - | $0 | Direct |
| Dec 19, 2025 | REPL Replimune Group, Inc. | Award(A) | 200,000 | - | - | Direct |
| Dec 2, 2025 | REPL Replimune Group, Inc. | Sale(S) | 10,000 | $11.13 | $111,300 | Direct |
| Jun 26, 2025 | RVMD Revolution Medicines, Inc. | Award(A) | 3,142 | - | - | Direct |
| May 20, 2025 | REPL Replimune Group, Inc. | Sale(S) | 25,105 | $8.06 | $202,346 | Direct |
| Apr 1, 2025 | REPL Replimune Group, Inc. | Award(A) | 166,667 | - | - | Direct |
| Dec 16, 2024 | REPL Replimune Group, Inc. | Sale(S) | 10,000 | $12.42 | $124,200 | Direct |
| Oct 31, 2024 | RVMD Revolution Medicines, Inc. | Exercise(M) | 5,000 | $24.84 | $124,200 | Direct |
| Oct 31, 2024 | RVMD Revolution Medicines, Inc. | Sale(S) | 5,000 | $54.14 | $270,715 | Direct |
1-22 of 22 transactions
About Patel Sushil
Patel Sushil (SEC CIK 0001860609) files insider reports with the SEC as Chief Executive Officer of Replimune Group, Inc. (REPL) and Director of Revolution Medicines, Inc. (RVMD).
Signal8 holds 12 ownership filings by Patel Sushil, all Form 4s, filed between Nov 4, 2024 and Aug 12, 2026. Those filings report 22 transactions, from Oct 31, 2024 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Patel Sushil's filings is in WOBURN, MA.
Recent filings by Patel Sushil
- Aug 10, 2026: Open-market sale of REPL shares (Form 4, code S).
- Jun 29, 2026: Open-market sales of RVMD shares (7 lines, Form 4, code S).
- Jun 29, 2026: Option exercise of RVMD shares (Form 4, code M).
- Jun 29, 2026: Open-market sales of RVMD shares (2 lines, Form 4, code S).
- Jun 18, 2026: Grant or award of RVMD shares (Form 4, code A).
Other insiders filing for Replimune Group, Inc. (REPL)
- Astley-Sparke Philip, Director
- Hill Emily Luisa, Chief Financial Officer
- Xynos Konstantinos, Chief Medical Officer
- Schwendenman Andrew, Chief Accounting Officer
- BAKER BROS. ADVISORS LP, Director
- Sarchi Christopher, Chief Commercial Officer